Advancing therapies for rare diseases
Eiger Biopharmaceuticals (eigerbio.com) scores 53 out of 100 on Brand Analyzer, placing it in the Early Stage tier among Healthcare brands, in the 2nd percentile of 8492 Healthcare brands.
Eiger Biopharmaceuticals is a biopharmaceutical company headquartered in Palo Alto, United States, founded in 2008. It focuses on developing and delivering innovative treatments for patients with rare and life-threatening diseases. The company maintains a diverse pipeline of therapies aimed at addressing unmet medical needs in underserved patient populations, working with healthcare providers and the medical research community.
| Brand Name | Eiger Biopharmaceuticals |
|---|---|
| Domain | eigerbio.com |
| Industry | Healthcare |
| Founded | 2008 |
| Headquarters | Palo Alto |
| Main Competitors | Ultragenyx Pharmaceutical (79/100), BioMarin Pharmaceutical (84/100), PTC Therapeutics (85/100), Alnylam Pharmaceuticals (87/100), Horizon Therapeutics (80/100), Amryt Pharma |
Moz Domain Authority 42/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "To develop and deliver innovative treatments for patients with rare and life-threatening diseases." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on Facebook, Instagram; no detected presence on X (Twitter), LinkedIn, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Eiger Biopharmaceuticals's main competitors in Healthcare: Ultragenyx Pharmaceutical (79/100), BioMarin Pharmaceutical (84/100), PTC Therapeutics (85/100), Alnylam Pharmaceuticals (87/100), Horizon Therapeutics (80/100).
Sources: Brand Analyzer scan
Eiger Biopharmaceuticals has limited AI-search visibility, scoring 27/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 29, recommendation 35). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Eiger Biopharmaceuticals was founded in 2008. Eiger Biopharmaceuticals operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Eiger Biopharmaceuticals is headquartered in Palo Alto. Eiger Biopharmaceuticals operates in the Healthcare category.
Sources: Wikidata
Eiger Biopharmaceuticals scores 35/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Eiger Biopharmaceuticals is a biopharmaceutical company based in Palo Alto, United States, founded in 2008. It develops treatments for rare and life-threatening diseases, aiming to serve patient populations with limited existing treatment options.
Eiger Biopharmaceuticals develops and delivers innovative treatments for patients with rare and serious diseases. It maintains a diverse pipeline of therapeutic candidates intended to address unmet medical needs where few treatment options currently exist.
Eiger Biopharmaceuticals can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Eiger Biopharmaceuticals is known for its focus on rare and difficult-to-treat diseases and for pursuing a diverse pipeline of therapies aimed at underserved patient populations that lack adequate treatment options.
Eiger Biopharmaceuticals' offerings are intended for patients suffering from rare and serious diseases, as well as healthcare providers and the medical research community who engage with its therapeutic pipeline and research efforts.
Eiger Biopharmaceuticals scores 27/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Eiger Biopharmaceuticals has a weak AI-visibility profile at 27/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (35/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a Moz Domain Authority of 42/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Eiger Biopharmaceuticals: DrugDangers (53/100), DNA Pharmacy (53/100), Five Star Senior Living (53/100), Hooper Holmes (53/100).
A step up - brands to learn from: Werskincare (56/100), Mercè Puig | Espai de Salut (56/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.